Search hospitals > Virginia > Fairfax
Inova Schar Cancer Institute
Claim this profileFairfax, Virginia 22031
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Squamous Cell Carcinoma
Conducts research for Solid Tumors
Conducts research for Melanoma
159 reported clinical trials
27 medical researchers
Summary
Inova Schar Cancer Institute is a medical facility located in Fairfax, Virginia. This center is recognized for care of Cancer, Breast Cancer, Squamous Cell Carcinoma, Solid Tumors, Melanoma and other specialties. Inova Schar Cancer Institute is involved with conducting 159 clinical trials across 184 conditions. There are 27 research doctors associated with this hospital, such as Janakiraman Subramanian, David P. Lee, MD, Adam Cohen, MD, and Raymond C Wadlow, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Janakiraman SubramanianSaint Luke's Hospital of Kansas City5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
20 drugs studied
David P. Lee, MDStanford Hospital and Clinics6 years of reported clinical research
Studies High Blood Pressure
Studies Vascular Disease
10 reported clinical trials
15 drugs studied
Adam Cohen, MDInova Schar Cancer Institute1 year of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
10 reported clinical trials
21 drugs studied
Raymond C Wadlow, MDInova Schar Cancer Institute2 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
8 reported clinical trials
17 drugs studied
Clinical Trials running at Inova Schar Cancer Institute
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Esophageal Carcinoma
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Gallbladder Cancer
Pancreatic Cancer
Solid Tumors
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Targeted Therapy
for Solid Tumors
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Inova Schar Cancer Institute?
Inova Schar Cancer Institute is a medical facility located in Fairfax, Virginia. This center is recognized for care of Cancer, Breast Cancer, Squamous Cell Carcinoma, Solid Tumors, Melanoma and other specialties. Inova Schar Cancer Institute is involved with conducting 159 clinical trials across 184 conditions. There are 27 research doctors associated with this hospital, such as Janakiraman Subramanian, David P. Lee, MD, Adam Cohen, MD, and Raymond C Wadlow, MD.